OHSU leadership on stage at AACR
Dozens of OHSU Knight Cancer Institute researchers commanded the spotlight at the American Association for Cancer Research Annual Meeting in Orlando, Florida. Lisa Coussens, Ph.D., who concluded...
Tag: pharmaceutical industry
Cancer costs: Marketing and myth busting
More than half of cancer drugs approved in recent years may not be helping patients to live longer. Meanwhile, the average price of cancer drugs has been increasing by 10 percent annually for more...
A new line of attack on deadly prostate cancers
Researchers have uncovered a potential drug target for stopping castration-resistant prostate tumors – the second leading cause of cancer death in the U.S. For decades, drug development for...
Taking stock of the evidence for ‘off-label’ use of cancer drugs
Doctors often expand the use of cancer drugs to situations beyond those explicitly approved by the Food and Drug Administration. And health plans will pay for those uses as long as they are supported...
Unmasking the cost of cancer drug development
Cancer drug R&D spending may be a fraction of the estimate cited by the biopharmaceutical industry. The average price of anticancer drugs has been rising by about 10 percent annually in...
When cancer drug marketing sneaks into a soap opera plot
Polycythemia vera is an uncommon blood cancer that can be controlled with long-established treatments. So it seemed more than a little suspicious to Vinay Prasad, M.D., M.P.H., when the disease took...
Old cancer drugs, spendy new prices
Prices of older cancer drugs are rising much more steeply than those of newer drugs, according to a study co-authored by an OHSU oncologist. Using Medicare data available for Part B, the...
Sizing up the FDA’s revolving door with industry
When reviewers with the Food and Drug Administration weigh the evidence for a drug company's experimental treatment, how many are thinking: I may someday work for that company? It's a difficult...
Cancer patient testimonials often tied to drug company money
Speakers who nominally represent cancer patients at advisory meetings on new drugs often have financial ties with the company seeking marketing approval. And those ties aren’t always disclosed,...